Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Healthtrust
Federal Trade Commission
Merck
Deloitte
Cantor Fitzgerald

Generated: September 17, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,782,402

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,782,402
Title:Injectable composition comprising buprenorphine
Abstract: The present invention is directed to a buprenorphine sustained release delivery system capable of delivering buprenorphine, a metabolite, or a prodrug thereof for a duration of about 14 days to about 3 months. The buprenorphine sustained release delivery system includes a flowable composition and a solid implant for the sustained release of buprenorphine, a metabolite, or a prodrug thereof. The implant is produced from the flowable composition. The buprenorphine sustained release delivery system provides in situ 1-month and 3-month release profiles characterized by an exceptionally high bioavailability and minimal risk of permanent tissue damage and typically no risk of muscle necrosis.
Inventor(s): Norton; Richard L. (Fort Collins, CO), Watkins; Andrew (Fort Collins, CO), Zhou; Mingxing (Fort Collins, CO)
Assignee: Indivior UK Limited (Berkshire, GB)
Application Number:15/334,000
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Compound;

Drugs Protected by US Patent 9,782,402

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Indivior Inc SUBLOCADE buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 209819-001 Nov 30, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATING ADDICTION BY SUBCUTANEOUS INJECTION OF BUPRENORPHINE ➤ Sign Up
Indivior Inc SUBLOCADE buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 209819-001 Nov 30, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATING ADDICTION WITH 100 MG OR 300 MG DOSE OF BUPRENORPHINE ➤ Sign Up
Indivior Inc SUBLOCADE buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 209819-001 Nov 30, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATING OPIOID ADDICTION BY ADMINISTERING BUPRENORPHINE ➤ Sign Up
Indivior Inc SUBLOCADE buprenorphine SOLUTION, EXTENDED RELEASE;SUBCUTANEOUS 209819-001 Nov 30, 2017 RX Yes No ➤ Sign Up ➤ Sign Up Y TREATING ADDICTION BY ONCE PER MONTH ADMINISTRATION OF BUPRENORPHINE ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Chubb
Boehringer Ingelheim
Queensland Health
Citi
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.